
C-Path's AI Collaborations Accelerate Drug Development, Improve Lives

TUCSON, Ariz., June 12, 2024— Critical Path Institute (C-Path) today announced the publication of a new peer-reviewed paper in the journal *Clinical and Translational Science*. As the preeminent leader in public-private partnerships to accelerate drug development, the paper highlights how C-Path's AI collaborations are revolutionizing drug development, with specific advancements in the management and treatment of Type 1 Diabetes (T1D) and Parkinson's Disease (PD). This study affirms the Institute's commitment to using artificial intelligence (AI) and digital health technologies (DHTs) to expedite the delivery of life-saving treatments.

Leading the initiative is Jagdeep Podichetty, Ph.D., Sr. Director of Predictive Analytics. Under Dr. Podichetty's leadership, the team's use of large language models (LLMs) has notably shortened development timelines for groundbreaking therapies in T1D and PD, directly impacting patient care, including pioneering tailored therapies that address the unique genetic markers identified in T1D and PD patients, potentially transforming treatment paradigms. This breakthrough promises to enhance patient care by making treatments for serious diseases available faster, thereby improving the quality of life for millions.

Titled "Accelerating Healthcare Innovation: The Role of Artificial Intelligence and Digital Health Technologies in Critical Path Institute's Public-private Partnerships," the paper is co-authored by C-Path team members Sakshi Sardar, Ph.D., Nick Henscheid, Ph.D., Grace V. Lee, Ph.D., J. Rubin Abrams, Ph.D., Wes Anderson, Ph.D., Shu Chin Ma, Ph.D., MSc., M. Phil, EMBA, and Klaus Romero, M.D., M.S., FCP. The paper is available for open access [here](#).

C-Path's neutrality and multi-stakeholder collaborations are key to its success in drug development. The Institute operates on five core competencies of excellence: data management and standards, modeling and analytics, biomarkers, clinical outcome assessments, and regulatory science.

As part of its excellence in model-informed drug development and quantitative medicine, C-Path has also developed expertise in real-world data and DHTs. This methodical and deliberate foundation allows C-Path to effectively leverage AI in the evolving landscape of drug development.

"C-Path's impact is global, with initiatives that span continents. Our patient-centered research in Type 1 Diabetes and Parkinson's Disease not only brings together global experts but also directly engages with patient communities to tailor interventions that meet their specific needs," said C-Path CEO Dr. Klaus Romero. "These collaborations are vital to our mission, enhancing our collective ability to generate groundbreaking solutions for pressing unmet needs in drug development."

"At C-Path, we believe every piece of data, every study, every project tells a story of someone waiting for better treatment," said Dr. Podichetty. "We are committed to turning these stories into realities of improved health and well-being."

The paper emphasizes C-Path's essential role in advancing AI and DHTs in drug development and the need for a unified approach to assess and implement these methodologies for drug development tools. C-Path's extensive experience in building trust among industry, government, academia, and patient advocacy groups underscores its capability to drive impactful and collaborative advancements, while also significantly

improving healthcare delivery and quality of life. This impact is amplified by C-Path's global initiatives, uniting experts from around the world to drive innovation and ensure the universal benefits of their research.

Romero added, "C-Path has a proven track record of success in accelerating drug development, as demonstrated by our impactful work in Alzheimer's disease, Type 1 diabetes prevention, Parkinson's disease, Friedreich's ataxia, Duchenne Muscular Dystrophy, polycystic kidney disease, and tuberculosis. But we're not stopping there. We're driving forward and building on this strong foundation to form partnerships that will advance treatment options for a wide array of diseases affecting people globally. C-Path is singularly positioned to make a significant impact on global health."

To learn more about C-Path's core competencies and work in AI, visit: <https://c-path.org/core-competencies/>

About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the [FDA's Critical Path Initiative](#). C-Path's mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is located in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.

Contacts:

Roxan Triolo Olivas
C-Path
520.954.1634
rolivas@c-path.org

Kissy Black
C-Path
615.310.1894
kblack@c-path.org